• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

利用 XTABLE 研究肺鳞癌通路功能障碍的癌前演变

Interrogating the precancerous evolution of pathway dysfunction in lung squamous cell carcinoma using XTABLE.

机构信息

Cancer Biomarker Centre, Cancer Research UK Manchester Institute, The University of Manchester, Macclesfield, United Kingdom.

Cancer Research UK Lung Cancer Centre of Excellence, Alderley Park, United Kingdom.

出版信息

Elife. 2023 Mar 9;12:e77507. doi: 10.7554/eLife.77507.

DOI:10.7554/eLife.77507
PMID:36892933
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10038660/
Abstract

Lung squamous cell carcinoma (LUSC) is a type of lung cancer with a dismal prognosis that lacks adequate therapies and actionable targets. This disease is characterized by a sequence of low- and high-grade preinvasive stages with increasing probability of malignant progression. Increasing our knowledge about the biology of these premalignant lesions (PMLs) is necessary to design new methods of early detection and prevention, and to identify the molecular processes that are key for malignant progression. To facilitate this research, we have designed XTABLE (Eploring rnscriptomes of ronchial esions), an open-source application that integrates the most extensive transcriptomic databases of PMLs published so far. With this tool, users can stratify samples using multiple parameters and interrogate PML biology in multiple manners, such as two- and multiple-group comparisons, interrogation of genes of interests, and transcriptional signatures. Using XTABLE, we have carried out a comparative study of the potential role of chromosomal instability scores as biomarkers of PML progression and mapped the onset of the most relevant LUSC pathways to the sequence of LUSC developmental stages. XTABLE will critically facilitate new research for the identification of early detection biomarkers and acquire a better understanding of the LUSC precancerous stages.

摘要

肺鳞状细胞癌（LUSC）是一种预后不良的肺癌，缺乏有效的治疗方法和可行的靶点。这种疾病的特征是一系列低级别和高级别癌前阶段，恶性进展的概率逐渐增加。为了设计新的早期检测和预防方法，并确定促进恶性进展的关键分子过程，我们有必要深入了解这些癌前病变（PMLs）的生物学特性。为了促进这项研究，我们设计了 XTABLE（支气管病变转录组学探索），这是一个开源应用程序，集成了迄今为止发表的最广泛的 PML 转录组数据库。使用这个工具，用户可以使用多个参数对样本进行分层，并以多种方式研究 PML 生物学，例如进行两组和多组比较、研究感兴趣的基因，以及转录特征分析。使用 XTABLE，我们进行了一项关于染色体不稳定性评分作为 PML 进展生物标志物的潜在作用的比较研究，并将最相关的 LUSC 通路的起始与 LUSC 发育阶段的顺序进行了映射。XTABLE 将极大地促进早期检测生物标志物的识别，并深入了解 LUSC 癌前阶段。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d860/10038660/126a5baceade/elife-77507-fig7-figsupp1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d860/10038660/a6d2cb7c5b21/elife-77507-fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d860/10038660/78bf14bcbea0/elife-77507-fig2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d860/10038660/a47d69b5ed1f/elife-77507-fig2-figsupp1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d860/10038660/b6a43ba14dde/elife-77507-fig2-figsupp2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d860/10038660/89c35ab51665/elife-77507-fig2-figsupp3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d860/10038660/d09d333e008b/elife-77507-fig3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d860/10038660/a724dcb523ab/elife-77507-fig4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d860/10038660/763fdc70bfbd/elife-77507-fig4-figsupp1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d860/10038660/4a60aeeb5ffe/elife-77507-fig5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d860/10038660/3a0103691218/elife-77507-fig6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d860/10038660/f83810c6220a/elife-77507-fig6-figsupp1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d860/10038660/f5976740c51e/elife-77507-fig6-figsupp2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d860/10038660/54b52a823a66/elife-77507-fig6-figsupp3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d860/10038660/7bdcafb38078/elife-77507-fig6-figsupp4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d860/10038660/e11f69ebf8ec/elife-77507-fig6-figsupp5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d860/10038660/d50ba03cf8a3/elife-77507-fig6-figsupp6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d860/10038660/b548541e9f8b/elife-77507-fig6-figsupp7.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d860/10038660/28cabf1c9c66/elife-77507-fig7.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d860/10038660/126a5baceade/elife-77507-fig7-figsupp1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d860/10038660/a6d2cb7c5b21/elife-77507-fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d860/10038660/78bf14bcbea0/elife-77507-fig2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d860/10038660/a47d69b5ed1f/elife-77507-fig2-figsupp1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d860/10038660/b6a43ba14dde/elife-77507-fig2-figsupp2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d860/10038660/89c35ab51665/elife-77507-fig2-figsupp3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d860/10038660/d09d333e008b/elife-77507-fig3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d860/10038660/a724dcb523ab/elife-77507-fig4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d860/10038660/763fdc70bfbd/elife-77507-fig4-figsupp1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d860/10038660/4a60aeeb5ffe/elife-77507-fig5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d860/10038660/3a0103691218/elife-77507-fig6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d860/10038660/f83810c6220a/elife-77507-fig6-figsupp1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d860/10038660/f5976740c51e/elife-77507-fig6-figsupp2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d860/10038660/54b52a823a66/elife-77507-fig6-figsupp3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d860/10038660/7bdcafb38078/elife-77507-fig6-figsupp4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d860/10038660/e11f69ebf8ec/elife-77507-fig6-figsupp5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d860/10038660/d50ba03cf8a3/elife-77507-fig6-figsupp6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d860/10038660/b548541e9f8b/elife-77507-fig6-figsupp7.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d860/10038660/28cabf1c9c66/elife-77507-fig7.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d860/10038660/126a5baceade/elife-77507-fig7-figsupp1.jpg

相似文献

1
Interrogating the precancerous evolution of pathway dysfunction in lung squamous cell carcinoma using XTABLE.利用 XTABLE 研究肺鳞癌通路功能障碍的癌前演变
Elife. 2023 Mar 9;12:e77507. doi: 10.7554/eLife.77507.
2
Convergence of YAP/TAZ, TEAD and TP63 activity is associated with bronchial premalignant severity and progression.YAP/TAZ、TEAD 和 TP63 活性的汇聚与支气管前恶性严重程度和进展相关。
J Exp Clin Cancer Res. 2023 May 8;42(1):116. doi: 10.1186/s13046-023-02674-5.
3
Multiple mutations of lung squamous cell carcinoma shared common mechanisms.肺鳞状细胞癌的多种突变具有共同机制。
Oncotarget. 2016 Nov 29;7(48):79629-79636. doi: 10.18632/oncotarget.13190.
4
Clinical value of miR-198-5p in lung squamous cell carcinoma assessed using microarray and RT-qPCR.采用微阵列和 RT-qPCR 评估 miR-198-5p 在肺鳞癌中的临床价值。
World J Surg Oncol. 2018 Feb 2;16(1):22. doi: 10.1186/s12957-018-1320-y.
5
Detecting the Presence and Progression of Premalignant Lung Lesions via Airway Gene Expression.通过气道基因表达检测癌前肺病变的存在和进展。
Clin Cancer Res. 2017 Sep 1;23(17):5091-5100. doi: 10.1158/1078-0432.CCR-16-2540. Epub 2017 May 22.
6
Transcriptome profiles of carcinoma-in-situ and invasive non-small cell lung cancer as revealed by SAGE.SAGE 揭示的癌前原位和浸润性非小细胞肺癌的转录组图谱。
PLoS One. 2010 Feb 11;5(2):e9162. doi: 10.1371/journal.pone.0009162.
7
Graph Perceiver Network for Lung Tumor and Bronchial Premalignant Lesion Stratification from Histopathology.基于图感知网络的肺肿瘤和支气管癌前病变组织病理分层。
Am J Pathol. 2024 Jul;194(7):1285-1293. doi: 10.1016/j.ajpath.2024.03.009. Epub 2024 Apr 6.
8
Molecular profiling of premalignant lesions in lung squamous cell carcinomas identifies mechanisms involved in stepwise carcinogenesis.肺鳞状细胞癌癌前病变的分子特征分析确定了逐步致癌过程中涉及的机制。
Cancer Prev Res (Phila). 2014 May;7(5):487-95. doi: 10.1158/1940-6207.CAPR-13-0372. Epub 2014 Mar 11.
9
Gene Expression Profiling Revealed 2 Types of Bronchial Basal Cell Hyperplasia and Squamous Metaplasia With Different Progression Potentials.基因表达谱揭示了具有不同进展潜能的两种支气管基底细胞增生和鳞状化生类型。
Appl Immunohistochem Mol Morphol. 2020 Jul;28(6):477-483. doi: 10.1097/PAI.0000000000000762.
10
System analysis of in LUAD and LUSC: The expression, prognosis, gene regulation network, and regulation targets.肺腺癌（LUAD）和肺鳞癌（LUSC）中 的系统分析：表达、预后、基因调控网络和调控靶点。
Int J Biol Markers. 2022 Jun;37(2):158-169. doi: 10.1177/03936155221084056. Epub 2022 Mar 7.

引用本文的文献

1
Real-Time Evolutionary Landscape of the Bronchial Epithelium and Corresponding Dynamic Immune Cell Alterations in Lung Squamous Cell Carcinogenesis.肺鳞状细胞癌发生过程中支气管上皮的实时进化景观及相应的动态免疫细胞改变
Adv Sci (Weinh). 2025 Aug;12(31):e13256. doi: 10.1002/advs.202413256. Epub 2025 Jun 5.
2
AKAP12, mediated by transcription factor 21, inhibits cell proliferation, metastasis, and glycolysis in lung squamous cell carcinoma.由转录因子21介导的AKAP12抑制肺鳞状细胞癌的细胞增殖、转移和糖酵解。
Open Life Sci. 2025 Apr 9;20(1):20220912. doi: 10.1515/biol-2022-0912. eCollection 2025.
3
A human model to deconvolve genotype-phenotype causations in lung squamous cell carcinoma.

本文引用的文献

1
Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries.《全球癌症统计数据 2020：全球 185 个国家和地区 36 种癌症的发病率和死亡率估计》。
CA Cancer J Clin. 2021 May;71(3):209-249. doi: 10.3322/caac.21660. Epub 2021 Feb 4.
2
Biomarker-driven therapies for previously treated squamous non-small-cell lung cancer (Lung-MAP SWOG S1400): a biomarker-driven master protocol.生物标志物驱动的治疗方案治疗既往治疗的鳞状非小细胞肺癌（Lung-MAP SWOG S1400）：一项生物标志物驱动的主方案。
Lancet Oncol. 2020 Dec;21(12):1589-1601. doi: 10.1016/S1470-2045(20)30475-7. Epub 2020 Oct 27.
3
一种用于解析肺鳞状细胞癌基因型-表型因果关系的人体模型。
Nat Commun. 2025 Apr 4;16(1):3215. doi: 10.1038/s41467-025-58343-y.
4
Transcript-Level Biomarkers of Early Lung Carcinogenesis in Bronchial Lesions.支气管病变中早期肺癌发生的转录本水平生物标志物
Cancers (Basel). 2024 Jun 18;16(12):2260. doi: 10.3390/cancers16122260.
Immune Surveillance in Clinical Regression of Preinvasive Squamous Cell Lung Cancer.
免疫监视在侵袭前鳞状细胞肺癌临床消退中的作用。
Cancer Discov. 2020 Oct;10(10):1489-1499. doi: 10.1158/2159-8290.CD-19-1366. Epub 2020 Jul 20.
4
The National Lung Matrix Trial of personalized therapy in lung cancer.国家肺癌矩阵试验：肺癌个体化治疗。
Nature. 2020 Jul;583(7818):807-812. doi: 10.1038/s41586-020-2481-8. Epub 2020 Jul 15.
5
Immune evasion before tumour invasion in early lung squamous carcinogenesis.肿瘤侵袭前的早期肺鳞癌免疫逃逸。
Nature. 2019 Jul;571(7766):570-575. doi: 10.1038/s41586-019-1330-0. Epub 2019 Jun 26.
6
Combination pembrolizumab plus chemotherapy: a new standard of care for patients with advanced non-small-cell lung cancer.帕博利珠单抗联合化疗：晚期非小细胞肺癌患者的新治疗标准
Lung Cancer (Auckl). 2019 Jun 4;10:47-56. doi: 10.2147/LCTT.S176391. eCollection 2019.
7
The emerging links between chromosomal instability (CIN), metastasis, inflammation and tumour immunity.染色体不稳定性（CIN）、转移、炎症与肿瘤免疫之间新出现的联系。
Mol Cytogenet. 2019 May 14;12:17. doi: 10.1186/s13039-019-0429-1. eCollection 2019.
8
Molecular subtyping reveals immune alterations associated with progression of bronchial premalignant lesions.分子亚型揭示了与支气管癌前病变进展相关的免疫改变。
Nat Commun. 2019 Apr 23;10(1):1856. doi: 10.1038/s41467-019-09834-2.
9
Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial.帕博利珠单抗对比化疗用于未经治疗、PD-L1 表达、局部晚期或转移性非小细胞肺癌（KEYNOTE-042）：一项随机、开放标签、对照、III 期临床试验。
Lancet. 2019 May 4;393(10183):1819-1830. doi: 10.1016/S0140-6736(18)32409-7. Epub 2019 Apr 4.
10
Deciphering the genomic, epigenomic, and transcriptomic landscapes of pre-invasive lung cancer lesions.解析肺癌前病变的基因组、表观基因组和转录组图谱。
Nat Med. 2019 Mar;25(3):517-525. doi: 10.1038/s41591-018-0323-0. Epub 2019 Jan 21.